Výsledky vyhledávání - "Kenneth C. Huber"

Resolution (and Late Recurrence) of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran

Autor: Michael L. Main, George G. Latus, Kenneth C. Huber, Abdul Qazi, Alan P. Wimmer

Publikováno v: Echocardiography. 33:792-795

The WATCHMAN left atrial (LA) appendage closure system is an alternative therapy for stroke prevention in patients with atrial fibrillation who are intolerant to chronic oral anticoagulation with warfarin. Infrequently, LA device-related thrombus (DR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80d5b7cf970a5e6cc71aa34706d28e95
https://doi.org/10.1111/echo.13174

Zobrazit plný text záznamu

Plný text ve formátu HTML

Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin

Autor: Jonathan L. Halperin, Kenneth C. Huber, Matthew J. Price, Nicole Gordon, Vivek Y. Reddy, Miguel Valderrábano, Douglas N. Gibson, David R. Holmes

Publikováno v: JACC: Cardiovascular Interventions. 8:1925-1932

Objectives The purpose of this study was to compare the relative risk of major bleeding with left atrial appendage (LAA) closure compared with long-term warfarin therapy. Background LAA closure is an alternative approach to chronic oral anticoagulati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71a4c88667a79dd69f5f5836d666a9fe
https://doi.org/10.1016/j.jcin.2015.08.035

Zobrazit plný text záznamu

Transesophageal echocardiographic diagnosis of a WATCHMAN left atrial appendage closure device thrombus 10 years following implantation

Autor: Keith B. Allen, Anthony Magalski, Kenneth C. Huber, Adnan K. Chhatriwalla, Michael L. Main, Shariq Shamim

Publikováno v: Echocardiography. 34:128-130

Left atrial appendage closure with the WATCHMAN device is an alternative to chronic oral anticoagulation for thromboembolic prophylaxis in atrial fibrillation patients. Left atrial device-related thrombus (DRT) has been described in the first year af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63821ea742f23209b4b0c78aa4d5c17a
https://doi.org/10.1111/echo.13413

Zobrazit plný text záznamu

Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy

Autor: David R. Holmes, Brian Whisenant, Matthew J. Price, Shephal K. Doshi, Saibal Kar, Vivek Y. Reddy, Horst Sievert, Kenneth C. Huber

Publikováno v: Journal of the American College of Cardiology. 64(1):1-12

Background: In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated patients with nonvalvular ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c572a1a5a196204c157ae599bb0890

Zobrazit plný text záznamu

Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial)

Autor: Michael L. Main, Shephal K. Doshi, Pamela S. Douglas, Nicole Gordon, Horst Sievert, Lawrence Liao, George G. Latus, Dali Fan, Vivek Y. Reddy, David R. Holmes, Dawn Rabineau, John A. House, R. Wright, Tina R. Coggins, Kenneth C. Huber

Publikováno v: The American journal of cardiology. 117(7)

Left atrial appendage closure with the WATCHMAN device is an alternative to anticoagulation for stroke prevention in selected patients with atrial fibrillation (AF). LA device-related thrombus (DRT) is poorly defined and understood. We aimed to (1) d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce44dd3e3d4922115f9f508fb9b304a
https://pubmed.ncbi.nlm.nih.gov/26993976

Zobrazit plný text záznamu

Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience

Autor: Matthew J, Price, Vivek Y, Reddy, Miguel, Valderrábano, Jonathan L, Halperin, Douglas N, Gibson, Nicole, Gordon, Kenneth C, Huber, David R, Holmes

Publikováno v: JACC. Cardiovascular interventions. 8(15)

The purpose of this study was to compare the relative risk of major bleeding with left atrial appendage (LAA) closure compared with long-term warfarin therapy.LAA closure is an alternative approach to chronic oral anticoagulation for the prevention o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a99b48a80b42894f2d8e711727438a9c
https://pubmed.ncbi.nlm.nih.gov/27101916

Zobrazit plný text záznamu

Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction

Autor: Charles W. Barth, Steven P. Marso, Warren L. Johnson, Barry D. Rutherford, Kenneth C. Huber, Steven B. Laster, Roberto A. Corpus, John A. House, William C. Daniels, Lee V. Giorgi, J. Aaron Grantham

Publikováno v: American Heart Journal. 148:493-500

The optimal percutaneous interventional strategy for dealing with significant non-culprit lesions in patients with multivessel disease (MVD) with acute myocardial infarction (AMI) at presentation remains controversial.A total of 820 patients treated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c48c50d61db5d2450bc1fea2c6f09942
https://doi.org/10.1016/j.ahj.2004.03.051

Zobrazit plný text záznamu

Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: An analysis of 25,223 patients over 20 years

Autor: Steven P. Marso, Steven B. Laster, Lee V. Giorgi, Kenneth C. Huber, Ben D. McCallister, Michael M. Coen, Cheryl J. Shelton, Warren L. Johnson, Barry D. Rutherford

Publikováno v: American Heart Journal. 145:270-277

Numerous studies have demonstrated that patients with diabetes have higher rates of restenosis, late myocardial infarction, and late death after percutaneous coronary interventions (PCI). However, it remains unclear whether patients with diabetes mel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ddf298ccf4a13f24664374d4b07f64
https://doi.org/10.1067/mhj.2003.56

Zobrazit plný text záznamu

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial

Autor: Vijay Swarup, Saibal Kar, Petr Neuzil, Jonathan L. Halperin, Brian Whisenant, Investigators, David R. Holmes, Shephal K. Doshi, Nicole Gordon, Vivek Y. Reddy, Kenneth C. Huber, Horst Sievert, Maurice Buchbinder

Publikováno v: JAMA. 312(19)

Importance While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions. Objective To determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a4badd7a889ca4fbb470a25c15e9a7
https://pubmed.ncbi.nlm.nih.gov/25894049

Zobrazit plný text záznamu

TCT-176 Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

Autor: David R. Holmes, Aaron D. Berman, Saibal Kar, George Hanzel, Steven L. Almany, Kenneth C. Huber

Publikováno v: Journal of the American College of Cardiology. 64(11)

Left atrial appendage closure (LAAC) is, intuitively, an attractive strategy to reduce stroke risk in atrial fibrillation. Although the PROTECT-AF trial demonstrated superiority of the WATCHMANTM LAAC device over warfarin at four years, there is litt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f341d0afa6ffdb4952de21393afbb5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání